- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00568126
Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females
August 12, 2020 updated by: David Mischoulon, MD, PhD, Massachusetts General Hospital
A Double-Blind, Placebo Controlled Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females
The purpose of this study is to find out whether Maca Root is effective for treating sexual dysfunction in females that is caused by antidepressant drugs.
An additional aim of the study is to document the safety and tolerability of maca root, as well as any potential side effects that it causes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a 12-week, double-blind, placebo-controlled trial comparing maca root (3.0 g/day) versus an inactive placebo in female outpatients with SSRI/SNRI-induced sexual dysfunction whose depression had remitted with SSRI treatment.
Outcome measures include improvement in sexual functioning as per the Arizona Sexual Experience Scale (ASEX) and the Massachusetts General Hospital Sexual Function Questionnaire (MGH-SFQ).
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Depression Clinical and Research Program, Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Subject is female, age 18 to 80 years
- Subject has been taking an SSRI, venlafaxine, or tri/heterocyclic antidepressant for the treatment of depression for at least 8 weeks; and is currently on a stable dose of the antidepressant for at least 4 weeks
- Subject is currently euthymic (HAM-D < 10) and is without significant anxiety symptoms (HAM-A < 10)
- Subject must have had no sexual dysfunction prior to taking antidepressant and there must be a clear temporal relationship between the sexual dysfunction and the antidepressant treatment
Subject must have been consistently experiencing at least one of the following criteria for at least 4 weeks, with distress or disability:
- Inability to have an orgasm, according to patient opinion
- Clinically significant orgasm delay with masturbation or intercourse
- Inability to attain or maintain until completion of sexual activity an adequate lubrication swelling response of sexual excitement
- Decreased libido according to patient opinion
- Subject must be having or had been having some form of regular sexual activity (masturbation, oral sex, intercourse) at least twice monthly prior to the antidepressant treatment and are willing to continue efforts at sexual activity at least once weekly for the duration of the study
- Subject must be in good general physical health
- Subject must be able to understand and communicate in English
- Subject must have given informed consent to participate in the study
Exclusion Criteria:
- Primary or prior diagnosis of a sexual disorder (other than the side effect of the bipolar medication or symptom of the bipolar disorder)
- Sexual dysfunction secondary to general underlying medical condition
- Penile, vaginal, clitoral or other sexual organ anatomical deformities
- Any uncontrolled psychiatric disorder
- Alcohol or substance abuse or dependence within the past six months
- Recent major relationship changes, disruption, or turmoil ongoing or anticipated which are unrelated to her sexual dysfunction
- Hamilton Depression and/or Anxiety Scale score (either) > 10
- Blood pressure outside the range of 90/50 - 170/100
- Known hyperprolactinemia
- Use of investigational drugs within previous 3 months or during study
- Current use of other drugs for antidepressant induced sexual dysfunction or other therapies or medications to treat sexual dysfunction
- Current use of nefazodone
- Hormone replacement therapy, unless patient has been on stable dose of hormone therapy for at least 3 mo prior to the antidepressant treatment and had no sexual dysfunction while on the same hormone therapy regimen, and there is no change in the HRT during the study
- Pregnancy, lactating, or planning to become pregnant during the study
- Child bearing potential subjects unwilling and/or not prepared and/or who are judged unreliable to use an acceptable and verifiable form of contraception during the study
- Any clinically significant abnormality on the screening physical examination
- History of hormonal cancers
- Any medical or psychological condition or social circumstances that would impair subject's ability to participate reliably in the study, or that may increase the risk to subjects or others as a result of participating in this study
- Dyspareunia secondary to an inflammatory or anatomical condition
- Prior use of maca for at least two weeks
- Infection of the urogenital tract that may make sexual activity painful or difficult
- Subjects whose sexual partners are suffering from and/or receiving treatment for sexual dysfunction
- Receiving psychosexual or other therapy for sexual dysfunction and not willing to discontinue that treatment at screening
- Subjects who do not understand and communicate in English
- Subjects for whom sexual activity is inadvisable
- Subjects whose sexual dysfunction is considered to be situational
- Subjects not attempting some form of regular sexual activity at least twice monthly and at least once weekly during study visit intervals for duration of entire study
- Changes in antidepressant agent and/or dose of medication within the last 4 weeks before baseline visit
- Participants on medications with a narrow therapeutic window or low therapeutic index for which small variations may be harmful given the lack of systematic experience with drug-supplement interactions (i.e. - cyclosporine, digoxin, warfarin, and antiretrovirals)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Maca Root
Subjects in this arm will be given 3g/day of maca root for 12 weeks
|
3g/day of Maca Root for 12 weeks.
Other Names:
|
Placebo Comparator: Placebo
Subjects in this arm will receive inactive placebo for 12 weeks.
|
Placebo provided by research pharmacy daily for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants in Remission Based on Arizona Sexual Experience Scale (ASEX) Score of 10 or Less After 12 Weeks of Treatment.
Time Frame: 12 weeks
|
Arizona Sexual Experience Scale (ASEX) consists of five items rating sexual drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm.The range of total score is 5-30 with the higher scores indicating greater sexual dysfunction.
A total final score of 10 or less is considered to indicate remission of sexual dysfunction.
|
12 weeks
|
Proportion of Participants in Remission Based on Massachusetts General Hospital Sexual Functioning Questionnaire (MGH-SFQ) Score of 12 or Less After 12 Weeks of Treatment.
Time Frame: 12 weeks
|
Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) is composed of five items evaluating libido, sexual arousal or excitement, ability to achieve orgasm, ability to achieve and maintain an erection (for men only) and overall sexual satisfaction.
Items are rated on a scale of 1 to 6 with a rating of 1 indicating greater than normal functioning and a rating of 6 indicating totally absent functioning.
A total final score of 12 or less is considered to indicate remission of sexual dysfunction.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Christina Dording, MD, Massachusetts General Hospital
- Study Director: David Mischoulon, MD, PhD, Massachusetts General Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 27, 2007
Primary Completion (Actual)
October 5, 2010
Study Completion (Actual)
October 5, 2010
Study Registration Dates
First Submitted
December 3, 2007
First Submitted That Met QC Criteria
December 3, 2007
First Posted (Estimate)
December 5, 2007
Study Record Updates
Last Update Posted (Actual)
August 26, 2020
Last Update Submitted That Met QC Criteria
August 12, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- 2007P001090
- R21AT004385 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
No current plan for this.
In the event that other researchers inquire about using our data (e.g. in a meta-analysis), we will evaluate how to proceed.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antidepressant Induced Sexual Dysfunction
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingEmergencies | Tricyclic Antidepressant Poisoning | Tricyclic Antidepressant ToxicityNetherlands
-
Thomas Jefferson UniversityCompletedAntidepressant Induced Excessive SweatingUnited States
-
University of British ColumbiaWithdrawnOther Substance Induced Sexual Dysfunction
-
RenJi HospitalRecruitingDyspepsia | Functional Gastrointestinal Disorders | Antidepressant Drug Adverse Reaction | Antidepressant Discontinuation SyndromeChina
-
Samsung Medical CenterUnknownDepression | Adverse Reaction to Drug | Continuous Antidepressant AbuseKorea, Republic of
-
Samsung Medical CenterH. Lundbeck A/SUnknownDevelopment of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide ScanningDepression | Adverse Reaction to Drug | Continuous Antidepressant AbuseKorea, Republic of
-
Samsung Medical CenterUnknownDepression | Antidepressant Drug Adverse ReactionKorea, Republic of
-
Stimdia Medical Inc.RecruitingVentilator Induced Diaphragm DysfunctionUnited States
-
Synapse BiomedicalActive, not recruitingVentilator Induced Diaphragm DysfunctionUnited States
-
Synapse BiomedicalCompletedVentilator-Induced Diaphragm DysfunctionUnited States
Clinical Trials on Maca Root
-
Massachusetts General HospitalCompletedDepression | Sexual DysfunctionUnited States
-
Massachusetts General HospitalNational Alliance for Research on Schizophrenia and DepressionTerminatedSexual Dysfunction | Bipolar DisorderUnited States
-
Taipei Medical UniversityNot yet recruiting
-
Taipei Medical UniversityPanion & BF Biotech Inc.Active, not recruiting
-
TC Erciyes UniversityCompletedPostoperative Pain
-
Institucion Universitaria Colegios de ColombiaCompleted
-
National Taiwan Sport UniversityCompleted
-
Luis Alberto Chauca BajañaUniversidad de GuayaquilNot yet recruitingGingival Recession | Gingival Recession, Localized
-
University of AarhusPrivate Hospital MoelholmRecruitingHerniated Disc | Radiculopathy Lumbar | Stenosis, Spinal | Foraminal Stenosis | Radiculopathy SacralDenmark
-
University of NebraskaCompletedPeriodontal Diseases | Periodontitis, Apical, Chronic Nonsuppurative | Suppuration of Gingival CreviceUnited States